$BIIB stock is trading near $188 — we rate Biogen a Buy with a $208 average analyst price target, and the risk/reward setup increasingly favours bulls after Q1 2026 delivered a 21% non-GAAP EPS beat, Leqembi sales jumped 74% year over year to $168 million, and Goldman Sachs raised its price target to $250 on accelerating Alzheimer's franchise momentum. Total Q1 revenue of $2.5 billion grew 2% — modest at the headline level but masked by the inflection inside Leqembi, which is now the highest-growth driver of the Biogen P&L. The BIIB stock price sits at a discount to the analyst average that reflects multiple-sclerosis franchise erosion concerns; that bear case is mechanically real, but the bull case on Leqembi plus the BIIB080 and BIIB122 mid-2026 pipeline readouts is increasingly the dominant Street narrative.
Key $BIIB Stock Data
| Metric | Value |
| Current Price | ~$188.00 |
| 52-Week Range | $140.00 – $235.00 |
| Market Cap | ~$27.5B |
| Q1 2026 Revenue | $2.5B (+2% YoY) |
| Q1 2026 Non-GAAP EPS | $3.57 (+18%, beat $2.95) |
| Leqembi Q1 Revenue | $168M (+74% YoY) |
| Analyst Consensus | Buy |
| Average Price Target | $208.00 |
| Street-High Target | $260 (BofA / Geoff Meacham) |
Table of Contents
- Key $BIIB Stock Data
- $BIIB Stock Key Takeaways
- What Is Biogen ($BIIB)?
- $BIIB Stock Q1 2026 Earnings and Leqembi Inflection
- $BIIB Stock Valuation Analysis
- Bullish and Bearish Analyst Opinions on Biogen
- $BIIB Analyst Targets and Stock Price Forecast
- $BIIB Pipeline: BIIB080, BIIB122, and Beyond
- $BIIB Stock FAQs
$BIIB Stock Key Takeaways
- Price and verdict. $BIIB trades near $188 with a Buy consensus and $208 average analyst target — about 11% headline upside, with a high target of $260 and a low of $143.
- Headline stat. Q1 2026 non-GAAP EPS of $3.57 beat consensus by 21%; Leqembi revenue of $168 million grew 74% YoY across the US, Japan, and China.
- Bull case. Leqembi inflection plus a pipeline that includes BIIB080 (tau-targeting Alzheimer's candidate) and BIIB122 (Parkinson's); Goldman Sachs raised target to $250 on Q1 print.
- Bear case. The multiple-sclerosis franchise faces biosimilar competition; FY26 total revenue may decline mid-single-digits to ~$9.4 billion; HSBC's low target of $143 anchors the bear thesis.
- What we'd watch. Leqembi quarterly revenue beats, BIIB080 and BIIB122 mid-2026 data readouts, and any commentary on MS franchise stabilisation.
What Is Biogen ($BIIB)?
Biogen Inc. (NASDAQ: BIIB) is a US biotechnology company headquartered in Cambridge, Massachusetts, focused on developing, manufacturing, and commercialising therapies for neurological, neuropsychiatric, and rare diseases. The company's commercial portfolio includes the multiple-sclerosis franchise (Tysabri, Tecfidera, Vumerity, Plegridy), the Alzheimer's franchise (Leqembi, co-developed with Eisai), the spinal muscular atrophy franchise (Spinraza), and a growing roster of rare-disease products (Skyclarys for Friedreich's ataxia, Qalsody for SOD1-ALS). Biogen also has a deep neurological pipeline that includes anti-tau, Parkinson's, and lupus-targeting candidates.
The $BIIB investment thesis is a two-track narrative. On the legacy MS franchise, biosimilar and generic competition has compressed prescription volume and pricing for years, which is why the company's overall revenue trajectory looks flat-to-down through 2026. On the growth-engine side, Leqembi is the single most important catalyst — the anti-amyloid Alzheimer's antibody is the first disease-modifying therapy to gain meaningful traction in the largest neurology market of the decade, with Q1 2026 sales up 74% year over year. Investors comparing Biogen against adjacent large-cap biotech compounders can layer in a watchlist that includes Amgen stock price for diversified biologics exposure and AbbVie stock price for a quality-and-income biopharma benchmark.
The rare-disease portfolio also deserves attention. Spinraza (SMA) has been a high-margin franchise for years, although it faces incremental competition from one-time gene therapies. Skyclarys (Friedreich's ataxia) and Qalsody (SOD1-ALS) are smaller commercial assets that diversify revenue away from the larger MS and Alzheimer's franchises. Combined with the partnerships with Sage Therapeutics on zuranolone (postpartum depression) and with Eisai on Leqembi, Biogen has built a portfolio model that hedges single-product concentration risk. The trade-off is that the rare-disease franchises are not large enough to fully offset MS decline — which is why the company's revenue trajectory still depends heavily on Leqembi acceleration over the next 24 to 36 months.
$BIIB Stock Q1 2026 Earnings and Leqembi Inflection
The Q1 2026 print was the clearest signal yet that the Leqembi launch is gathering momentum. Total revenue reached $2.5 billion, up 2% year over year — a modest headline that hid a much more interesting mix shift. GAAP diluted EPS came in at $2.15 (up 31%) and non-GAAP diluted EPS was $3.57 (up 18%), beating the $2.95 consensus by 21.02%. That magnitude of EPS beat is unusual for a large-cap biotech and was driven by both operating leverage and tighter cost discipline.
The Leqembi disclosure was the headliner. Q1 market revenue reached $168 million, up 74% year over year, with sequential growth in all three key markets — the United States, Japan, and China. The launch trajectory is finally clearing the patient-screening, MRI-monitoring, and infusion-capacity bottlenecks that constrained the first 12 months post-approval. Goldman Sachs reacted to the print by lifting the BIIB price target to $250 — meaningfully above the consensus average — explicitly citing Leqembi acceleration. The accompanying FDA LEQEMBI IQLIK (subcutaneous) review timeline could either compress (positive catalyst) or extend (negative catalyst), and that timing is the single highest-leverage swing variable on the $BIIB stock price over the next two quarters. The bear-case argument that the MS franchise erosion offsets Leqembi growth is now harder to defend given the 74% growth rate inside a market that is still expanding TAM.
$BIIB Stock Valuation Analysis
The $BIIB stock valuation discussion balances the legacy-franchise compression against the Leqembi acceleration and pipeline optionality. At $188 and 2026 consensus EPS of roughly $16 (mid-range), the forward P/E sits at about 12x — well below the broader biotech median in the high-teens. The table below shows how the multiple stacks across frameworks.
| Framework | Multiple | Implied Price | Comment |
| Legacy-pharma-decline | ~10x | ~$155 | Prices in MS franchise erosion |
| Current trading | ~12x | ~$188 | Mixed credit for Leqembi |
| Biotech sector avg | ~15x | ~$240 | Re-rate to peer multiple |
| Leqembi-blockbuster premium | ~17x | ~$275 | Bull case if Leqembi clears $4B annualized |
| Pipeline-optionality premium | — | ~$300+ | Adds BIIB080 / BIIB122 contributions |
The current forward P/E of roughly 12x looks low by absolute biotech standards, but consensus models project total revenue to decline mid-single-digit percent in FY26 (to ~$9.4 billion) before stabilising and re-accelerating in FY27 as Leqembi compounds. That decline-then-re-acceleration profile is unusual and explains the multiple compression. If Leqembi continues to grow at the 74% rate seen in Q1 and combines with even modest pipeline contribution, the multiple should re-rate toward the biotech sector average — implying $240+ for the stock. For a complete BIIB stock price analysis, model Leqembi's annual run-rate as the swing variable; every $500 million of incremental Leqembi revenue at a sector-average multiple adds roughly $10–15 per share.
Bullish and Bearish Analyst Opinions on Biogen
The 23 to 34 analysts covering BIIB stock split between Buy and Hold ratings, with one Sell holdout. The price-target spread is among the widest in large-cap biotech, which is exactly the setup that produces tradable opportunities when the trajectory clarifies.
| Camp | Firm / Analyst | Rating | Target | Thesis Driver |
| Most Bullish | BofA Securities / Geoff Meacham | Buy | $260 | Leqembi inflection plus pipeline optionality |
| Bullish | Goldman Sachs | Buy | $250 | Q1 beat plus accelerating Alzheimer's franchise |
| Constructive | Consensus Average | Buy | $208 | 11% implied upside on Buy/Hold mix |
| Cautious | Mid-Range Hold | Hold | $195 | MS franchise erosion balances Leqembi gains |
| Most Bearish | HSBC / Rajesh Kumar | Sell | $143 | Top-line decline risk plus biosimilar pressure |
The bullish view rests on three pillars. First, Leqembi's 74% Q1 revenue growth is the kind of inflection rate that historically precedes multi-year revenue compounding. Second, the BIIB080 (anti-tau) and BIIB122 (Parkinson's) pipeline catalysts arriving mid-2026 add optionality that is not yet in consensus models. Third, the 12x forward P/E creates a meaningful margin of safety if either catalyst lands. The bearish view focuses on near-term math: total revenue declines in FY26, biosimilar pressure on the MS franchise has been relentless, and Leqembi at $168 million per quarter is still small relative to the legacy franchise. Our read: the risk/reward favours bulls because the Q1 print explicitly validated the Leqembi acceleration thesis, while the bear case is already priced into the 12x multiple.
$BIIB Analyst Targets and Stock Price Forecast
The published 12-month analyst targets on $BIIB span $143 (HSBC low) to $260 (BofA high), with the consensus average between $198.22 and $208 across the most-cited datasets. We anchor on $208 as the most credible blend. From the current $188 print, the average implies roughly 11% upside; the BofA high target implies 38.6% upside; the HSBC low target implies 23.8% downside. The asymmetry of the upside vs downside isn't wildly skewed, but the catalyst path leans bullish given Q1 data.
Our base-case $BIIB stock price forecast for the next 12 months sits at $220 — a partial re-rate above the analyst average, justified by Q1 EPS momentum, Leqembi acceleration, and the pipeline-readout calendar. The bull case at $260 (matching BofA) requires Leqembi to clear an annualised $1 billion-plus run-rate by Q4 and at least one of BIIB080 or BIIB122 to deliver positive Phase 3 data. The bear case at $155 requires Leqembi growth to stall plus continued MS franchise erosion. Investors holding BIIB stock through the year should focus on Q2 Leqembi revenue (target: $200M+) and any commentary on subcutaneous-Leqembi (IQLIK) regulatory timeline.
$BIIB Pipeline: BIIB080, BIIB122, and Beyond
The two pipeline catalysts that most explicitly support the $BIIB stock bull case are BIIB080 and BIIB122, both expected to deliver mid-2026 data readouts. BIIB080 (tau-targeting antisense oligonucleotide for Alzheimer's disease) sits next to Leqembi in the Alzheimer's pipeline — if positive, it gives Biogen a second mechanism of action in the same therapeutic area, which historically commands premium multiples because of optionality on combination therapy. BIIB122 (LRRK2-targeting therapy for Parkinson's disease) opens a separate, large neurology TAM if the Phase 3 data is positive.
The pipeline value isn't in consensus EPS models, but it is reflected in some analyst price targets. The most bullish desks essentially add a pipeline-optionality premium of $30–50 per share on top of the base-business valuation. The path to that premium depends on data quality; positive readouts on either candidate would likely trigger a multiple expansion toward sector-average levels. Negative readouts would compress the multiple back toward the legacy-pharma-decline framework. Investors who want to track adjacent biotech compounders facing similar pipeline-vs-legacy dynamics can layer in a watchlist comparison against United Therapeutics stock price for a similar "legacy franchise plus growth pipeline" setup.
The clinical trial design matters here. BIIB080 (tau-targeting ASO) has been in development for nearly a decade and is one of the most-watched assets in the entire Alzheimer's pipeline because tau pathology is biologically distinct from amyloid pathology. A positive BIIB080 readout would position Biogen with disease-modifying assets covering both major Alzheimer's biomarkers — a unique commercial position. BIIB122 is in partnership with Denali Therapeutics and targets LRRK2 in Parkinson's disease, where current treatments are mostly symptomatic. Each candidate represents a multi-billion-dollar peak-sales opportunity if approved.
$BIIB Stock FAQs
Is $BIIB a good stock to buy in 2026?
For long-horizon biotech investors comfortable with catalyst-driven volatility, BIIB stock at $188 looks like a constructive Buy with 11% headline upside to the $208 average target and meaningful asymmetric upside if Leqembi compounds. The 12x forward P/E creates a margin of safety against the MS franchise erosion already priced in. The bull case rests on Leqembi's 74% Q1 growth rate and the BIIB080/BIIB122 pipeline-readout calendar.
What are the bullish and bearish analyst opinions on Biogen stock?
The spread is one of the widest in large-cap biotech. BofA Securities (Buy, $260) and Goldman Sachs (Buy, $250) anchor the bullish view on Leqembi acceleration and pipeline optionality. The consensus near $208 reflects mixed Buy/Hold ratings. HSBC (Sell, $143) leans on top-line decline risk and biosimilar pressure on the MS franchise. The dispersion itself is informative: BIIB is a name where the catalyst path can dramatically change the trajectory.
How did Leqembi perform in Q1 2026?
Leqembi global market revenue reached $168 million in Q1 2026, up 74% year over year, with sequential growth in the US, Japan, and China. The 74% growth rate is the highest among any Biogen product line and validates the disease-modifying-therapy thesis for Alzheimer's. The subcutaneous IQLIK formulation is under FDA review, which could meaningfully expand patient access if approved on the expected timeline.
What is the $BIIB stock price forecast for 2026?
Our 12-month base-case BIIB stock price forecast is $220 — a partial re-rate above the $208 analyst average. The bull case at $260 requires Leqembi to hit $1B+ annualised plus at least one positive pipeline readout. The bear case at $155 requires Leqembi to stall plus continued MS franchise erosion. The Street-high target is $260 (BofA); the low is $143 (HSBC).
Does Biogen pay a dividend?
Biogen does not currently pay a regular cash dividend. Capital returns are concentrated in selective share buybacks plus pipeline reinvestment. The reinvestment-heavy approach is consistent with biotech industry norms for companies with substantial pipeline catalysts; investors prioritise EPS growth from new product launches over dividend payouts. If Leqembi compounds as expected, Biogen could revisit its capital-allocation framework in the back half of 2026.
Disclaimer
This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Past performance does not guarantee future results. Investors should conduct thorough due diligence and consult qualified financial advisors before making investment decisions.
MEXC is a global cryptocurrency exchange committed to “MEXCmize Your Opportunities.” Serving over 40 million users across 170+ countries, MEXC offers access to more than 3,000 digital assets across spot and derivatives markets. Known for its high liquidity and broad selection of trending tokens, the platform is designed to support both new traders and experienced investors. MEXC also continues to enhance trading efficiency through innovations such as zero trading fees, while prioritizing a secure, user-friendly, and accessible trading experience. Select MEXC as Your 0-fee Gateway To Infinite Opportunities.